Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TLPH vs AQST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AQST Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

AQST Overall Winner 6-Pillar Tally: TLPH 2 – 3 AQST (1 Tie) Matrix Metrics: TLPH 4 – 6 AQST

As of Nov 16, 2026, Aquestive Therapeutics, Inc. (AQST) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas AQST carries 59.4/100 (HOLD) at $3.77 (N/M Forward P/E, -114.1% operating margin).

  • Growth vs. Quality Trade-Off: AQST earns the overall head-to-head edge with a stronger Unified Composite Score (59.4/100 HOLD vs. TLPH 37.1/100 SELL) and 0.87β · 56% Vol risk profile, whereas TLPH leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLPH vs AQST
TLPH NASDAQ
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10
AQST NASDAQ Head-to-Head Winner
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.77
-3.45% 1D
Market Cap $448.7M
TTM Revenue $49M
Forward P/E N/M
Beta / 30D Vol 0.87β · 56% Vol
Unified Composite Score
59.4 / 100 HOLD
Tech 69.0 Fund 66.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 44
RSI-14: 43.7 · SMA20: $3.85 · SMA50: $4.34

6-Pillar Scorecard Institutional Category Breakdown (TLPH 2 – 3 AQST)

Columns: Metric · TLPH · AQST
1. Valuation Multiples TLPH
Forward P/E 1.0x N/M
Trailing P/E 1.0x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 8.5x
2. Growth & Scale AQST
Revenue Growth (YoY) +0.0% -41.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1,000 $49M
Market Cap $53.7M $448.7M
3. Profitability & Quality AQST
Gross Margin N/A 65.3%
Operating Margin -1474700.0% -114.1%
Net Profit Margin 0.0% -162.3%
Return on Equity (ROE) -143.4% 0.0%
4. Balance Sheet & Cash Flow AQST
Cash Generation (TTM) -$15M EBITDA -$41M
Cash Flow Margin N/A -83.3%
Net Cash / Leverage $0.28 Book/Sh · -143.4% ROE $32M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TLPH
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 118.4% (100th %ile) 61.9% (40th %ile)
Put/Call OI Skew N/A 0.38x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLPH (4) vs AQST (6)
Institutional Metric TLPH AQST Criterion Row Edge
Market Capitalization
Scale
$53.7M $448.7M Larger Scale AQST
Trailing P/E Ratio
Valuation
1.0x N/M Lower Multiple TLPH
Forward P/E Ratio
Valuation
1.0x N/M Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+0.0% -41.0% Higher Growth TLPH
Operating Margin (TTM)
Profitability
-1474700.0% -114.1% Higher Margin AQST
Net Profit Margin
Profitability
0.0% -162.3% Higher Margin TLPH
Return on Equity (ROE)
Capital Efficiency
-143.4% 0.0% Higher ROE AQST
52-Week Range Position
Momentum
20% ($1–$2) 22% ($3–$7) Stronger Trend AQST
Beta / 30D Volatility
Risk Regime
1.11β · 58% Vol 0.87β · 56% Vol Lower Realized Risk AQST
Unified Institutional Score
Composite Signal
37.1 / 100 (SELL) 59.4 / 100 (HOLD) Higher Composite AQST
Trailing 12M Revenue (USD)
Operating Scale
$1,000 $49M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 65.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 8.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) -$41M ($32M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AQST +20.16 pp
TLPH: -20.29% · AQST: -0.13%
3M Horizon AQST +16.23 pp
TLPH: -28.85% · AQST: -12.62%
6M Horizon TLPH +16.69 pp
TLPH: +7.98% · AQST: -8.71%
1Y Horizon TLPH +10.76 pp
TLPH: -18.01% · AQST: -28.77%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLPH vs AQST. Trailing 12-month operating profitability (TLPH -1474700.0% vs AQST -114.1%) and valuation multiples (TLPH 1.0x vs AQST N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x
AQST ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin65.3%
Op. Margin-114.1%
ROE / Fwd P/E0.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AQST BREAKDOWN
57d in phase · OBV DISTRIBUTION
Current IV 61.9%
IV Percentile 40th %ile
Put/Call OI Skew 0.38x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AQST Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $448.7M market capitalization and -114.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TLPH vs AQST Key Questions & Quantitative Answers

As of Nov 16, 2026, Aquestive Therapeutics, Inc. (AQST) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas AQST carries 59.4/100 (HOLD) at $3.77 (N/M Forward P/E, -114.1% operating margin). Growth vs. Quality Trade-Off: AQST earns the overall head-to-head edge with a stronger Unified Composite Score (59.4/100 HOLD vs. TLPH 37.1/100 SELL) and 0.87β · 56% Vol risk profile, whereas TLPH leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AQST leads the Growth & Scale pillar: TLPH posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin), compared with AQST at -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin). On trailing 12-month operating scale, TLPH generates $1,000 in USD-normalized revenue versus $49M for AQST. In operating R&D and SG&A reinvestment, TLPH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AQST.

TLPH screens cheaper on headline valuation multiples. TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.5x EV/Revenue (-83.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLPH (-143.4% ROE) versus AQST (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk). By comparison, AQST carries 61.9% implied volatility (40th %ile, Balanced (25th–60th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.87β · 56% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.